share_log

Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary

Important Biotech Catalysts For September 13, 2022 - End Of The Day Summary

2022年9月13日的重要生物技術催化劑-當天結束摘要
Benzinga Real-time News ·  2022/09/13 18:46
Akero Therapeutics (NASDAQ:AKRO) revealed topline data from HARMONY, a 24-week Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin (EFX) in patients with pre-cirrhotic nonalcoholic steatohepatitis (NASH), the study met its primary endpoint for both the 50mg and 28mg EFX dose groups. Akero Therapeutics shares traded as high as 142.3 percent, in a range of $25.01 to $29.73 on day volume of 49.46 million shares versus three months average volume of 406.52 thousand shares, closed regular trading session at $29.05. The company shares traded at $28.2, down 2.93 percent in the after-hours trading session.
Akero治療公司納斯達克(Sequoia Capital:AKRO)公佈了來自Harmonity的TOPLINE數據,這是一項為期24周的2b期研究,評估其主導產品候選藥物依夫西弗明(EFX)對肝硬變前非酒精性脂肪性肝炎(NASH)患者的療效和安全性,該研究達到了50毫克和28毫克EFX劑量組的主要終點。Akero Treateutics的股票交易量高達142.3%,當日成交量為4,946萬股,區間為25.01美元至29.73美元,而三個月平均成交量為406.52萬股,常規交易時段收盤時為29.05美元。該公司股價為28.2美元,在盤後交易中下跌2.93%。
Akouos (NASDAQ:AKUS) has received clearance from the U...
阿庫斯納斯達克股票...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論